| Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate ... - WELT ONLINE |
|
|
WELT ONLINESeattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and ...Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate ... read more |